Molecular and Clinical Data of Antimicrobial Resistance in Microorganisms Producing Bacteremia in a Multicentric Cohort of Patients with Cancer in a Latin American Country
- PMID: 36838324
- PMCID: PMC9960769
- DOI: 10.3390/microorganisms11020359
Molecular and Clinical Data of Antimicrobial Resistance in Microorganisms Producing Bacteremia in a Multicentric Cohort of Patients with Cancer in a Latin American Country
Abstract
Patients with cancer have a higher risk of severe bacterial infections. This study aims to determine the frequency, susceptibility profiles, and resistance genes of bacterial species involved in bacteremia, as well as risk factors associated with mortality in cancer patients in Colombia. In this prospective multicenter cohort study of adult patients with cancer and bacteremia, susceptibility testing was performed and selected resistance genes were identified. A multivariate regression analysis was carried out for the identification of risk factors for mortality. In 195 patients, 206 microorganisms were isolated. Gram-negative bacteria were more frequently found, in 142 cases (68.9%): 67 Escherichia coli (32.5%), 36 Klebsiella pneumoniae (17.4%), and 21 Pseudomonas aeruginosa (10.1%), and 18 other Gram-negative isolates (8.7%). Staphylococcus aureus represented 12.4% (n = 25). Among the isolates, resistance to at least one antibiotic was identified in 63% of them. Genes coding for extended-spectrum beta-lactamases and carbapenemases, blaCTX-M and blaKPC, respectively, were commonly found. Mortality rate was 25.6% and it was lower in those with adequate empirical antibiotic treatment (22.0% vs. 45.2%, OR: 0.26, 95% CI: 0.1-0.63, in the multivariate model). In Colombia, in patients with cancer and bacteremia, bacteria have a high resistance profile to beta-lactams, with a high incidence of extended-spectrum beta-lactamases and carbapenemases. Adequate empirical treatment diminishes mortality, and empirical selection of treatment in this environment of high resistance is of key importance.
Keywords: adults; bacteremia; beta-lactamases; drug resistance; infection; microbial; neoplasm.
Conflict of interest statement
J.A.C. and C.A.Á.-M. have a research grant sponsored by Pfizer and the International Society of Infectious Diseases. C.H.S.-T. has research grants sponsored by Merck and Pfizer. A.L.L. has research grants sponsored by Merck Sharp and Dohme and Pfizer. The other authors have no conflicts of interest to declare.
Similar articles
-
Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.J Microbiol Immunol Infect. 2012 Jun;45(3):193-9. doi: 10.1016/j.jmii.2011.11.003. Epub 2012 May 12. J Microbiol Immunol Infect. 2012. PMID: 22580086
-
[Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].Sheng Wu Gong Cheng Xue Bao. 2018 Aug 25;34(8):1205-1217. doi: 10.13345/j.cjb.180192. Sheng Wu Gong Cheng Xue Bao. 2018. PMID: 30152206 Chinese.
-
Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes.J Clin Microbiol. 1999 Dec;37(12):4020-7. doi: 10.1128/JCM.37.12.4020-4027.1999. J Clin Microbiol. 1999. PMID: 10565924 Free PMC article.
-
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16. Drugs. 2022. PMID: 35294769 Review.
-
Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.Am J Med. 1996 Jun 24;100(6A):3S-12S. doi: 10.1016/s0002-9343(96)00102-7. Am J Med. 1996. PMID: 8678095 Review.
Cited by
-
Etiology, Risk Factors, and Outcomes of Bacteremia in Patients With Hematologic Malignancies and Febrile Neutropenia in Uganda.Open Forum Infect Dis. 2024 Nov 16;11(12):ofae682. doi: 10.1093/ofid/ofae682. eCollection 2024 Dec. Open Forum Infect Dis. 2024. PMID: 39660025 Free PMC article.
-
Seven-day antibiotic therapy for Enterobacterales bacteremia in high-risk neutropenic patients: toward a new paradigm.Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1741-1751. doi: 10.1007/s10096-024-04885-w. Epub 2024 Jul 3. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38958809
-
Ceftazidime-Avibactam Improves Outcomes in High-Risk Neutropenic Patients with Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales Bacteremia.Microorganisms. 2024 Jan 18;12(1):195. doi: 10.3390/microorganisms12010195. Microorganisms. 2024. PMID: 38258022 Free PMC article.
-
[Nine-year trend in Escherichia coli resistance to ciprofloxacin: cross-sectional study in a hospital in Colombia].Cad Saude Publica. 2024 Aug 26;40(7):e00031723. doi: 10.1590/0102-311XES031723. eCollection 2024. Cad Saude Publica. 2024. PMID: 39194094 Free PMC article. Spanish.
-
Epidemiology of Bacteremia in Patients with Hematological Malignancies and Hematopoietic Stem Cell Transplantation and the Impact of Antibiotic Resistance on Mortality: Data from a Multicenter Study in Argentina.Pathogens. 2024 Oct 26;13(11):933. doi: 10.3390/pathogens13110933. Pathogens. 2024. PMID: 39599486 Free PMC article.
References
-
- Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., Raad I.I., Rolston K.V., Young J.A., Wingard J.R., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2011;52:427–431. doi: 10.1093/cid/ciq147. - DOI - PubMed
-
- Cortes J.A., Cuervo S., Gomez C.A., Bermudez D., Martinez T., Arroyo P. Febrile neutropenia in the tropics: A description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. Biomedica. 2013;33:70–77. doi: 10.1590/S0120-41572013000100009. - DOI - PubMed
-
- World Health Organization . Global Action Plan on Antimicrobial Resistance. WHO; Geneva, Switzerland: 2015. pp. 1–28.
Grants and funding
LinkOut - more resources
Full Text Sources